Nectin Therapeutics

Next-generation Immunotherapy Agents

Health Tech & Life Sciences
Active
Series A Jerusalem, Israel Founded 2017
Last updated 2026-06-18
Total raised
$36.0M
Last: 2024-05
Stage
Series A
Founded
2017
Headcount
11
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

Nectin Therapeutics is a biotechnology company devoted to transforming the lives of cancer patients by the development of next-generation immune-oncology (IO) therapies. The company is dedicated to the development of novel therapeutic options for cancer patients. It is developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, it develops CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers. The company was established based on seminal research at the Hebrew University of Jerusalem and the University of Rijeka. Its technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates.

Funding history · 6 rounds · $36.0M total

Q&A

What is Nectin Therapeutics' primary focus?
Nectin Therapeutics is a biotechnology company dedicated to developing next-generation immune-oncology (IO) therapies to transform the lives of cancer patients.
When was Nectin Therapeutics founded?
Nectin Therapeutics was founded in January 2017.
What is Nectin Therapeutics' current employee count?
Nectin Therapeutics has 11-50 employees.
What is Nectin Therapeutics' total funding to date?
Nectin Therapeutics has raised a total of $36,000,000 USD.
Which investors participated in Nectin Therapeutics' May 2024 funding round?
In May 2024, Guangzhou Sino-Israel Biotech Investment Fund (GIBF) invested in Nectin Therapeutics.
Who led Nectin Therapeutics' December 2022 funding round?
The December 2022 funding round for Nectin Therapeutics was led by.
Who is the CEO of Nectin Therapeutics?
Fabian Tenenbaum is the CEO of Nectin Therapeutics.
What is the product stage of Nectin Therapeutics?
Nectin Therapeutics' product is in the clinical trial stage.
Where is Nectin Therapeutics headquartered?
Nectin Therapeutics is headquartered in Jerusalem, Israel, with an additional office in Fort Lee, NJ, USA.

Team · 11

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

biotechnologypharmaceuticalsoncologyimmunologycancer-therapycancerantibodiespatientsdrug-deliverytreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitenectintx.com
LinkedInlinkedin.com/company/69206104

Identifiers & details

Founded2017-1
Employees (exact)11
OfficesFort Lee

Radar intelligence

Patents

EPO6

Web history (Wayback)

Domainnectintx.com

Certificate / subdomain footprint

Subdomains3